Sophia Genetics SA has welcomed Amrita Hospital in Faridabad, India, to its network, enhancing its capabilities in the realm of precision medicine. Amrita Hospital will utilize the SOPHiA DDM™ platform to aid in the diagnosis and treatment of rare disorders and cancers, with a focus on exome, solid tumor, and blood cancer applications. This collaboration will allow Amrita Hospital to perform testing in-house, resulting in faster turnaround times for clinicians and researchers. Dr. Moushumi Suryavanshi, Head of Molecular Biology at Amrita Hospital, emphasized the importance of this partnership in providing advanced Next Generation Sequencing testing. The integration into the SOPHiA GENETICS network will also enable Amrita Hospital to contribute valuable insights from Indian genomic data to a global community. Ricardo Ramos Mendonca Filho, Managing Director of LAPAC at SOPHiA GENETICS, highlighted the mission to democratize data-driven medicine and enhance patient care worldwide through this collaboration.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。